Biogen Idec Releases During AAN

Just received from Biogen Idec:

Please find below links to three Biogen Idec press releases that were distributed during AAN. The releases included data showing TYSABRI may have the potential to remyelinate brain lesions, patients reported a better quality of life after only three months of TYSABRI treatment, and AVONEX patients who started treatment shortly after their first attack fared better than those who delayed treatment.

• MRI DATA SHOWING TYSABRI® PROMOTED REMYELINATION PRESENTED AT THE 61ST ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY
• New Tysabri(R) Data Demonstrate Significant Effects On Health-Related Quality Of Life Measures In Multiple Sclerosis Patients
  
• First Ten-Year Follow-Up Shows That Treatment with AVONEX® Leads to Long-Term Benefits in Early Multiple Sclerosis Patients